Andrew Palmer
Acute Care · Lansing, MINPI 1629555768
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 439 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 439 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Grifols USA, LLC$941
- GSK$926
- Mylan Specialty L.p.$489
- Jazz Pharmaceuticals Inc.$473
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,53495%
- Education$4125%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 99 | $2,100 |
| Boehringer Ingelheim | 62 | $1,293 |
| Grifols USA, LLC | 50 | $941 |
| GSK | 59 | $926 |
| Mylan Specialty L.p. | 25 | $489 |
| Jazz Pharmaceuticals Inc. | 18 | $473 |
| Regeneron Healthcare Solutions, Inc. | 23 | $440 |
| Actelion Pharmaceuticals US, Inc. | 15 | $392 |
| Sanofi | 19 | $386 |
| Sanofi-aventis U.S. LLC | 3 | $223 |
| Viatris Specialty LLC | 11 | $172 |
| United Therapeutics Corporation | 6 | $130 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $112 |
| Amgen | 6 | $104 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Insmed, Inc. | 5 | $80 |
| Bayer | 4 | $79 |
| Inspire Medical Systems, Inc. | 1 | $76 |
| Philips North America LLC | 4 | $62 |
| Harmony Biosciences LLC | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Genentech USA, Inc. | 2 | $43 |
| Verona Pharma, Inc. | 2 | $42 |
| 3b Medical, Inc. | 1 | $39 |
| Merck | 2 | $33 |
| Bard Peripheral Vascular, Inc. | 1 | $25 |
| Electromed, Inc. | 3 | $24 |
| Melinta Therapeutics, LLC | 1 | $21 |
| Vapotherm Inc | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Covis Pharma GmbH | 1 | $12 |
| Pulmonx Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,946 in reported general payments places this provider in the 95th percentile of 567 acute care providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 238 | $271,475 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 110 | $103,241 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $50,484 |
| Spiriva RespimatTiotropium Bromide | 49 | $46,242 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 53 | $38,938 |
| Breo ElliptaFluticasone/Vilanterol | 62 | $35,704 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $21,373 |
| DuleraMometasone/Formoterol | 41 | $18,715 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $12,027 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 224 | $8,975 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $8,932 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $7,716 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $5,910 |
| Arnuity ElliptaFluticasone Furoate | 16 | $4,818 |
| Montelukast Sodium | 183 | $3,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $926 | $350,935369 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,100 | $124,614158 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,293 | $105,658138 claims |
| MerckDulera | $33 | $18,71541 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $13 | $7,71611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 acute care providers in Michigan.
Other acute care in Lansing
- Jennifer RutzenLansing$7K
- Bridgette ArnalLansing$2K
- Janet WymanDetroit$103K
- Stephanie Mellon ReppenDetroit$57K
- Ashley WozniakLivonia$26K
- Julia BriggsBirch Run$16K
- Candise LovePort Huron$14K
- Janette GuertinPort Huron$14K
- Gregory AliNovi$13K
- Angela BrennanDearborn Heights$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.